Impact of different patient and transplant characteristics on LFS, RI, NRM, OS, neutrophil engraftment, and GVHD in multivariate Cox regression analysis
| Parameter . | LFS . | RI . | NRM . | OS . | NEG . | aGVHD . | cGVHD . |
|---|---|---|---|---|---|---|---|
| ALL vs AML | 1.33 (1.27-1.39)† | 1.31 (1.23-1.40)† | 1.35 (1.25-1.45)† | 1.29 (1.22-1.35)† | 0.92 (0.89-0.96)† | 1.21 (1.12-1.30)† | 1.05 (0.99-1.12) |
| Age at least 42 y | 1.28 (1.22-1.34)† | 1.08 (1.01-1.15)‡ | 1.59 (1.47-1.70)† | 1.35 (1.28-1.41)† | 0.96 (0.92-0.99)‡ | 1.03 (0.95-1.11) | 1.16 (1.09-1.23)† |
| Female donor to male recipient vs other combination | 1.02 (0.97-1.08) | 0.95 (0.89-1.02) | 1.13 (1.04-1.22)‡ | 1.05 (0.99-1.11) | 0.92 (0.89-0.96)† | 1.12 (1.03-1.22)‡ | 1.28 (1.20-1.37)† |
| HLA-identical sibling vs other donor type | 0.89 (0.85-0.93)† | 1.10 (1.04-1.17)‡ | 0.66 (0.61-0.71)† | 0.83 (0.79-0.87)† | 1.20 (1.16-1.24)† | 0.82 (0.76-0.88)† | 0.98 (0.93-1.04) |
| RIC vs MAC | 1.04 (0.99-1.10) | 1.28 (1.20-1.38)† | 0.77 (0.71-0.85)† | 0.99 (0.93-1.04) | 0.97 (0.93-1.01) | 0.77 (0.70-0.84)† | 0.90 (0.84-0.97)‡ |
| CR vs other disease status | 0.50 (0.48-0.52)† | 0.45 (0.42-0.47)† | 0.58 (0.54-0.62)† | 0.49 (0.47-0.51)† | 1.05 (1.02-1.09)‡ | 0.90 (0.84-0.97)‡ | 0.91 (0.86-0.97)‡ |
| PB vs BM | 1.09 (1.04-1.15)‡ | 1.10 (1.03-1.18)‡ | 1.08 (1.00-1.17)‡ | 1.09 (1.04-1.15)‡ | 1.89 (1.82-1.97)† | 0.84 (0.78-0.91)† | 1.40 (1.31-1.50)† |
| Allo-SCT after the year 2004 | 0.89 (0.85-0.93)† | 0.95 (0.90-1.01) | 0.81 (0.75-0.87)† | 0.88 (0.84-0.92)† | 0.94 (0.91-0.97)‡ | 0.90 (0.83-0.97)‡ | 0.98 (0.93-1.04) |
| D-CMV+/R-CMV– vs D-CMV–/R-CMV– | 1.12 (1.04-1.21)‡ | 1.12 (1.01-1.24)‡ | 1.13 (1.00-1.28)‡ | 1.16 (1.07-1.26)‡ | 1.03 (0.97-1.10) | 1.10 (0.97-1.24) | 1.05 (0.95-1.15) |
| D-CMV–/R-CMV+ vs D-CMV–/R-CMV– | 1.10 (1.04-1.17)‡ | 1.03 (0.95-1.12) | 1.20 (1.09-1.32)‡ | 1.14 (1.07-1.21)‡ | 0.99 (0.94-1.03) | 0.97 (0.87-1.07) | 1.01 (0.93-1.10) |
| D-CMV+/R-CMV+ vs D-CMV–/R-CMV– | 1.13 (1.07-1.20)† | 1.08 (1.01-1.16)‡ | 1.21 (1.11-1.32)† | 1.15 (1.09-1.22)† | 1.00 (0.96-1.04) | 0.92 (0.85-1.01) | 0.98 (0.92-1.05) |
| D-CMV+/R-CMV+ vs D-CMV–/R-CMV+* | 0.97 (0.92-1.03) | 1.05 (0.97-1.13) | 1.00 (0.92-1.09) | 0.99 (0.93-1.05) | 0.99 (0.95-1.03) | 1.05 (0.95-1.15) | 1.03 (0.96-1.11) |
| D-CMV–/R-CMV– vs all other* | 0.89 (0.85-0.94)† | 0.93 (0.87-0.99)‡ | 0.84 (0.77-0.90)† | 0.87 (0.83-0.92)† | 1.00 (0.97-1.04) | 1.04 (0.96-1.13) | 1.00 (0.94-1.06) |
| Parameter . | LFS . | RI . | NRM . | OS . | NEG . | aGVHD . | cGVHD . |
|---|---|---|---|---|---|---|---|
| ALL vs AML | 1.33 (1.27-1.39)† | 1.31 (1.23-1.40)† | 1.35 (1.25-1.45)† | 1.29 (1.22-1.35)† | 0.92 (0.89-0.96)† | 1.21 (1.12-1.30)† | 1.05 (0.99-1.12) |
| Age at least 42 y | 1.28 (1.22-1.34)† | 1.08 (1.01-1.15)‡ | 1.59 (1.47-1.70)† | 1.35 (1.28-1.41)† | 0.96 (0.92-0.99)‡ | 1.03 (0.95-1.11) | 1.16 (1.09-1.23)† |
| Female donor to male recipient vs other combination | 1.02 (0.97-1.08) | 0.95 (0.89-1.02) | 1.13 (1.04-1.22)‡ | 1.05 (0.99-1.11) | 0.92 (0.89-0.96)† | 1.12 (1.03-1.22)‡ | 1.28 (1.20-1.37)† |
| HLA-identical sibling vs other donor type | 0.89 (0.85-0.93)† | 1.10 (1.04-1.17)‡ | 0.66 (0.61-0.71)† | 0.83 (0.79-0.87)† | 1.20 (1.16-1.24)† | 0.82 (0.76-0.88)† | 0.98 (0.93-1.04) |
| RIC vs MAC | 1.04 (0.99-1.10) | 1.28 (1.20-1.38)† | 0.77 (0.71-0.85)† | 0.99 (0.93-1.04) | 0.97 (0.93-1.01) | 0.77 (0.70-0.84)† | 0.90 (0.84-0.97)‡ |
| CR vs other disease status | 0.50 (0.48-0.52)† | 0.45 (0.42-0.47)† | 0.58 (0.54-0.62)† | 0.49 (0.47-0.51)† | 1.05 (1.02-1.09)‡ | 0.90 (0.84-0.97)‡ | 0.91 (0.86-0.97)‡ |
| PB vs BM | 1.09 (1.04-1.15)‡ | 1.10 (1.03-1.18)‡ | 1.08 (1.00-1.17)‡ | 1.09 (1.04-1.15)‡ | 1.89 (1.82-1.97)† | 0.84 (0.78-0.91)† | 1.40 (1.31-1.50)† |
| Allo-SCT after the year 2004 | 0.89 (0.85-0.93)† | 0.95 (0.90-1.01) | 0.81 (0.75-0.87)† | 0.88 (0.84-0.92)† | 0.94 (0.91-0.97)‡ | 0.90 (0.83-0.97)‡ | 0.98 (0.93-1.04) |
| D-CMV+/R-CMV– vs D-CMV–/R-CMV– | 1.12 (1.04-1.21)‡ | 1.12 (1.01-1.24)‡ | 1.13 (1.00-1.28)‡ | 1.16 (1.07-1.26)‡ | 1.03 (0.97-1.10) | 1.10 (0.97-1.24) | 1.05 (0.95-1.15) |
| D-CMV–/R-CMV+ vs D-CMV–/R-CMV– | 1.10 (1.04-1.17)‡ | 1.03 (0.95-1.12) | 1.20 (1.09-1.32)‡ | 1.14 (1.07-1.21)‡ | 0.99 (0.94-1.03) | 0.97 (0.87-1.07) | 1.01 (0.93-1.10) |
| D-CMV+/R-CMV+ vs D-CMV–/R-CMV– | 1.13 (1.07-1.20)† | 1.08 (1.01-1.16)‡ | 1.21 (1.11-1.32)† | 1.15 (1.09-1.22)† | 1.00 (0.96-1.04) | 0.92 (0.85-1.01) | 0.98 (0.92-1.05) |
| D-CMV+/R-CMV+ vs D-CMV–/R-CMV+* | 0.97 (0.92-1.03) | 1.05 (0.97-1.13) | 1.00 (0.92-1.09) | 0.99 (0.93-1.05) | 0.99 (0.95-1.03) | 1.05 (0.95-1.15) | 1.03 (0.96-1.11) |
| D-CMV–/R-CMV– vs all other* | 0.89 (0.85-0.94)† | 0.93 (0.87-0.99)‡ | 0.84 (0.77-0.90)† | 0.87 (0.83-0.92)† | 1.00 (0.97-1.04) | 1.04 (0.96-1.13) | 1.00 (0.94-1.06) |
Shown are hazard ratios with 95% confidence interval (n = 16 628).
aGVHD, acute GVHD; cGVHD, chronic GVHD; NEG, neutrophil engraftment.
These comparisons have been done in separate multivariate Cox regression analyses, including all patient and transplant characteristics besides the CMV serostatus as specified in this table.
P < .0001.
P < .05.